RilvegostomigNSCLCnon-small cell lung cancer
…o TIGIT-expressing cells, even in mixed populations.Conclusions Rilvegostomig’s potent, preferential TIGIT binding and cooperative PD-1 engag…
4articles mentioning drugs
29drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: rilvegostomig ×
rilvegostomig
This drug is selected. Its supporting articles are shown below.
Articles mentioning rilvegostomig
4 articles · page 1 of 1Rilvegostomignon-small cell lung cancerNSCLCHBS regulatory board
… rilvegostomig activity from conventional anti-PD-(L)1 therapy. Rilvegostomig was active in tumors with unique driver mutations, lower CD8+ T…
Puxi-samsaruparibrilvegostomigInstitutional Animal Care and Use Committee of Astrazeneca
…ceive either monotherapy doublet or triple combination therapy. Puxi-sam was administered as a single i.v. dose at 7 mg/kg, saruparib wa…
TIGIT inhibitorsEtigilimabRilvegostomigTIGIT inhibitorPD1 inhibitorDargistotugBAT6021tiragolumab
…clinical trials of TIGIT inhibitors should be questioned. Seven TIGIT inhibitors (all Fc-enabled) did not recapitulate in clinical trials the pr…